Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19UCART in Relapsed/Refractory B-Cell Hematologic Malignancies
NCT07316907Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in B-cell hematologic malignancy. Primary endpoints: Toxicity and adverse-event grading at 12 months and Cytokine Release Syndrome grading at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
UCART19
03
Conditions
B-cell hematologic malignancy
Beyond the preview
Go deeper on NCT07316907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07316907.